Just one IPO is currently scheduled to list in the week ahead, although some small issuers may join the calendar during the week.
Holdover Actuate Therapeutics (ACTU) is scheduled to raise $27 million at a $182 million market cap. Actuate has exclusively licensed a portfolio of glycogen synthase kinase-3 (GSK-3) inhibitors, with the goal of targeting difficult to treat cancers. Its lead candidate is being evaluated in a Phase 2 trial in metastatic pancreatic cancer, with top line results expected in the 1Q25.
| U.S. IPO Calendar | |||
|---|---|---|---|
| Issuer Business | Deal Size Market Cap | Price Range Shares Filed | Top Bookrunners |
| Actuate Therapeutics (ACTU) Fort Worth, TX | $27M $182M | $8 - $10 2,950,000 | Titan Partners |
| Phase 2 biotech developing an inhibitor therapy for difficult to treat cancers. | |||
Sign up for a free trial of our premium platform, IPO Pro. To get our IPO calendar in your inbox, register here.
Lock-up periods will be expiring for six companies. For access to lock-up expiration dates, sign up for a free trial of IPO Pro.
IPO Market Snapshot
The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 8/1/2024, the Renaissance IPO Index was up 2.6% year-to-date, while the S&P 500 was up 15.1%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Kenvue (KVUE) and Nu Holdings (NU). The Renaissance International IPO Index was down 7.3% year-to-date, while the ACWX was up 7.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Amman Mineral Internasional and Barito Renewables Energy.
